驱动蛋白E g5在非小细胞肺癌中的表达及其意义

目的：检测驱动蛋白Eg5在非小细胞肺癌（NSCLC）中的表达水平，并探讨其与非小细胞肺癌转移的关系。方法：选取63例非小细胞肺癌的手术切除标本和20例正常肺脏组织标本，采用免疫组化检测Eg5的表达，并分析其与非小细胞肺癌临床病理特征和转移之间的关系。结果：E g5在正常肺组织中未见明显表达，在非小细胞肺癌组织中的表达阳性率为68．3％（43／63），且与非小细胞肺癌的肿瘤直径（χ2＝4．506，P＝0．034）、临床分期（χ2＝8．866，P＝0．012）、淋巴结转移情况（χ2＝19．52，P＜0．001）有关，差异有统计学意义；而与患者性别、年龄、分化程度等指标无明显的相关性（P＞0．05）。结论：Eg5在正常肺组织中未见明显表达，在非小细胞肺癌组织中高表达，E g5的表达与非小细胞肺癌临床分期及转移有关，E g5可预测非小细胞肺癌的淋巴结转移情况，可能作为非小细胞肺癌化学治疗的潜在靶点。

The expression and significance of kinesin Eg5 in non-small cell lung cancer

Objective:To investigate the expression level of kinesin Eg5 in non-small cell lung cancer(NSCLC), and to explore its relation with metastasis of non-small cell lung cancer.Methods:To select 63 cases with non-small cell lung cancer surgical resection specimens and 20 cases of normal lung tissue samples,Eg5 expression was detected by immunohistochemistry,and its relation with clinical pathological features and metastasis of non-small cell lung cancer was analysed.Results:Immunohistochemistry showed Eg5 in normal lung tissue was not-obviously ex-pressed,in non-small cell lung cancer overall expression positive rate was 68.3%(43/63),which was obviously re-lated to the tumor diameter(χ2 =4.506,P=0.034),clinical stage(χ2 =8.866,P=0.012),lymph node metastasis (χ2 =19.52,P<0.001 ),and the difference was statistically significant.There was no significant correlation with gender,age,degree of differentiation,and other indicators(P>0.05 ).Conclusion:Eg5 in normal lung tissue,there was no obvious expression while there was high expression in non-small cell lung cancer which was closely related to its clinical stage and metastasis.Eg5 can predict the lymph node metastasis of non-small cell lung cancer and may be a potential target in its therapeutics.